By Kevin Dunleavy
With pressure mounting domestically and abroad for COVID-19 vaccine supplies, the Serum Institute of India is asking its country for assistance in boosting production of the AstraZeneca shot.
read more
By Angus Liu
The feds stopped distributing Eli Lilly's and AbCellera's COVID drug bamlanivimab as a monotherapy, out of concern that it may not be effective against new coronavirus variants. Now the companies have new findings that they believe provide support for the drug to be used with another antibody to protect against those variants.
read more
By Conor Hale
After reaping a windfall from COVID-19 diagnostic demand, Hologic’s spending spree continues with its largest acquisition yet: It’s claimed Mobidiag, the Finnish-French molecular test maker, with a $795 million deal.
read more
By Robert King
CMS is proposing slight pay bumps for both rehab and psychiatric facilities for the 2022 fiscal year that starts in October, and has new requirements to track COVID-19 vaccinations.
read more
By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky
BeiGene's phase 2 trial of Brukinsa on COVID patients requiring oxygen failed to reach its endpoints. The Serum Institute of India has asked its government for a $400 million grant to bump up production of AstraZeneca COVID-19 vaccines. The FDA has approved an at-home COVID-19 antibody test for the first time. And more headlines.
read more
By Eric Sagonowsky
Bristol Myers Squibb’s February approval for CAR-T lymphoma med Breyanzi came after multiple delays that ended up costing investors in a big way. FDA documents now offer clues about what went wrong, a biotech analyst writes.
read more
By Ben Adams
CytoDyn has lost its chief scientific officer Mahboob Rahman, M.D., Ph.D., just six months into his tenure at the biotech.
read more
